Novo Nordisk's Wegovy Pill Wins EU Approval as CagriSema's FDA Verdict Becomes the Next Key Catalyst
Published on 07/20/2026 at 20:12 | Redaktion boerse-global.de
Novo Nordisk has just opened a fresh growth lever in Europe with the approval of its oral Wegovy tablet, but the stock's trajectory remains tethered to a separate regulatory decision across the Atlantic. The Danish drugmaker secured EU marketing authorization for the first GLP-1 weight-loss pill on July 15, 2026, giving patients an alternative to weekly injections. Yet the shares, currently trading at around EUR 43.80, still sit nearly 28% below their all-time high of EUR 60.95, underscoring how much hinges on the U.S. Food and Drug Administration's verdict on the experimental candidate CagriSema, expected before the end of next year.
The Wegovy tablet addresses a critical bottleneck: convenience. By replacing the injection regimen with a once-daily pill, Novo hopes to broaden the addressable market, improve adherence, and attract patients who shunned needles. The company's push into oral delivery is reinforced by a USD 360 million production facility in the Czech Republic that has recently begun operations, easing the capacity constraints that have dogged the franchise. In the United States, a new Medicare GLP-1 Bridge that took effect on July 1 caps monthly copays at USD 50 for eligible patients, a move likely to boost prescription volumes. Together, these developments are fueling a 30-day rally of more than 12% that has carried the stock off its March lows.
But the bullish narrative has a prominent asterisk. CagriSema, a combination therapy designed to compete head-to-head with Eli Lilly's tirzepatide, stumbled in the Phase III REDEFINE 4 trial. Among 809 participants, the drug produced a mean weight loss of 23% over 84 weeks, compared with 25.5% for tirzepatide, failing to demonstrate non-inferiority. That outcome, while not a safety failure, leaves the FDA application in a precarious position. An unrestricted approval would signal that regulators see sufficient differentiation, while a rejection or highly restrictive label could deal a severe blow to Novo's ambition to reclaim market share in the fast-growing obesity space.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The competitive stakes are stark. In the combined U.S. GLP-1 market for obesity and diabetes, Lilly commands a 60.1% share, leaving Novo with 39.4%. Lilly is not standing still: it is advancing its own oral candidate, Foundayo, and has filed for approval in roughly 40 countries. A price war looms as more entrants crowd the field, and Novo's shares have shed about 0.5% year-to-date, reflecting lingering margin concerns.
To shore up confidence, Novo has deployed a substantial buyback program. Since February, it has committed up to DKK 15 billion over a 12-month window, and by July 10 it had repurchased nearly 24 million B-shares at an average price of DKK 272.45. The company is also grooming the next pipeline candidate: Amycretin, another weight-loss compound, is scheduled to enter Phase III in the first quarter of 2026. Meanwhile, Ozempic sales slipped 8% year-on-year, but the overall obesity business expanded 22% on a currency-adjusted basis, propelled almost entirely by the launch of the Wegovy tablet.
Technical indicators suggest the recovery still has room to run. The relative strength index hovers near 61, comfortably below overbought territory, and the stock has cleared both its 50-day moving average of EUR 40.11 and the 200-day moving average of EUR 40.46. A sustained move above these levels could open a path back toward the 52-week high, provided upcoming catalysts cooperate.
Those catalysts arrive in quick succession. On July 27, Novo will debut "Extensior" in South Africa — a lower-cost variant of Ozempic aimed at emerging markets. The quarterly earnings report, due August 5, will offer a clearer window into whether oral Wegovy volume gains can offset ongoing share losses in the injectable segment. But it is the CagriSema decision — whether delayed, denied, or delivered with restrictions — that will ultimately determine whether the current rally becomes a durable trend or merely a pause before another retreat toward the year's lows near EUR 30.25.
Ad
Novo Nordisk Stock: New Analysis - 20 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
